Gastrointestinal cancer cells treatment with bevacizumab activates a VEGF autoregulatory mechanism involving telomerase catalytic subunit hTERT via PI3K-AKT, HIF-1α and VEGF receptors

BACKGROUND: Targeting angiogenesis has been considered a promising treatment of choice for a large number of malignancies, including gastrointestinal cancers. Bevacizumab is an anti-vascular endothelial growth factor (anti-VEGF) being used for this purpose. However, treatment efficacy is largely que...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahfouz, Nadine, Tahtouh, Roula, Alaaeddine, Nada, El Hajj, Joelle, Sarkis, Riad, Hachem, Ray, Raad, Issam, Hilal, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466359/
https://www.ncbi.nlm.nih.gov/pubmed/28594907
http://dx.doi.org/10.1371/journal.pone.0179202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466359/
https://www.ncbi.nlm.nih.gov/pubmed/28594907
http://dx.doi.org/10.1371/journal.pone.0179202

Ejemplares similares